Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial...

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Homozygous familial hypercholesterolemia (HoFH) patients face high cardiovascular risks due to premature atherosclerosis.
• Limited efficacy of current pharmacological therapies for HoFH necessitates novel treatment strategies.

Purpose of the Study:

• To evaluate the efficacy, safety, and tolerability of ezetimibe, a cholesterol absorption inhibitor, in HoFH patients.
• To compare the effects of ezetimibe plus statins versus statins alone on LDL cholesterol levels.

Main Methods:

• A multicenter, double-blind, randomized trial involving 50 HoFH patients on background statin therapy.
• Patients were randomized to receive high-dose statins alone or in combination with ezetimibe for 12 weeks.
• LDL apheresis was used in a subset of patients.

Main Results:

• Ezetimibe plus statins significantly reduced LDL cholesterol compared to high-dose statins alone (-20.7% vs -6.7%, P=0.007).
• Adding ezetimibe to high-dose statins achieved further significant LDL-C reductions (20.5% additional reduction, P=0.0001).
• Ezetimibe was found to be safe and well-tolerated in this patient population.

Conclusions:

• Coadministration of ezetimibe with atorvastatin or simvastatin yields clinically significant LDL cholesterol reductions in HoFH patients.
• Ezetimibe represents a valuable, complementary pharmacological option for managing HoFH, a high-risk cardiovascular group.